Market capitalization | $1.68b |
Enterprise Value | $1.22b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.27 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-129.72m |
Free Cash Flow (TTM) Free Cash Flow | $-94.43m |
Cash position | $489.88m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
11 Analysts have issued a Gemini Therapeutics Inc forecast:
11 Analysts have issued a Gemini Therapeutics Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.16 -0.16 |
30%
30%
|
|
EBITDA | -130 -130 |
43%
43%
|
EBIT (Operating Income) EBIT | -130 -130 |
42%
42%
|
Net Profit | -109 -109 |
43%
43%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | John Quisel |
Employees | 84 |
Founded | 2017 |
Website | www.discmedicine.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.